ABVX · Abivax SA
$131.16
+1.10% last session
End-of-day data · updated 2026-07-25
Market cap
$11B
Enterprise value
$10B
Trailing P/E
—
Forward P/E
-40.0
Dividend yield
—
Beta
-0.21
Avg volume
2M
Employees
0K
2D change
-4.16%
5D change
-4.41%
10D change
-8.21%
30D change
36.08%
60D change
-0.56%
MTD change
-5.18%
YTD change
-6.79%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ABVX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-09
Latest call per bank · past 12 months
Jefferies
Buy$158
+20.5% vs priceMorgan Stanley
Overweight$132
+0.6% vs priceBarclays
Overweight$148
+12.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-09 | Piper Sandler | Maintains | Overweight | $165 → $175 |
| 2026-07-02 | Truist Securities | Maintains | Buy | $135 → $155 |
| 2026-07-01 | Citizens | Reiterates | Market Outperform | $187 |
| 2026-06-30 | Jefferies | Upgrade | Hold → Buy | $108 → $158 |
| 2026-06-30 | Leerink Partners | Maintains | Outperform | $140 → $148 |
| 2026-06-30 | Wedbush | Maintains | Neutral | $90.00 → $110 |
| 2026-06-30 | BTIG | Maintains | Buy | $150 → $175 |
| 2026-06-16 | BTIG | Reiterates | Buy | $150 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.4% above the 50-day MA ($117.74).
- Price vs 200-day MA: Trading 13.2% above the 200-day MA ($115.81).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.16) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($66.49) and high ($145.31).
ABVX Price Chart
Loading chart for ABVX…
Fundamentals
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.